Prometheus Biosciences, Inc.
DelistedCIK 1718852fmd_1JYNX6CM482S78S6XP2N8GSV2CManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Mar 31, 2023, 13 periods
| Line item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Total revenues | 1 | 3 | 7 |
| Research and development | 19 | 62 | 113 |
| Total operating expenses | 30 | 91 | 153 |
| Operating income | (29) | (88) | (146) |
| Interest expense | 2 | 1 | – |
| Interest and investment income | 0 | 0 | 4 |
| Other non-operating income (expense) | (2) | (2) | 4 |
| Income tax expense | – | 0 | 0 |
| Net income from continuing operations | (31) | (90) | (142) |
| Net income | (37) | (90) | (142) |